Dockery LE, et al. - Researchers sought to assess the overall tolerability and toxicity of olaparib capsules among older (≥ 65 years) patients with recurrent ovarian cancer treated on 8 completed prospective trials of olaparib. Women ≥65 years and < 65 years of age treated for advanced recurrent ovarian cancer indicated similar tolerability and toxicity of olaparib capsules. They recommended considering the use of olaparib in this patient population.